September 2026
2026-09-30 ⚗️ 4 💻 1 🏢 3
Five science items, from an amatoxin ADC payload SAR study to siderophore-vectored MBL inhibitors, plus three business stories: Genentech–Earendil's AI bispecific pact, Mirum's hepatitis delta Phase 3 win and Tolerance's Tanabe IL-33 in-license.
2026-09-29 ⚗️ 6 🏢 6
Six science picks span hit-finding platforms to a MurB PET probe; six business items include Kodiak's Eylea-rival trial win, Mirum's third FOP approval, a Merck/Daiichi ADC withdrawal, a Merck KRAS licensing deal, AbbVie's Parkinson's nod, and a Maruho-BMS Japan tie-up.
2026-09-28 ⚗️ 5 🏢 5
Science: p53 Y220C engagement, covalent macrocycle libraries, methyl-mimic bioisosteres, a fluorinated apoptosis scaffold, and cell-penetrating poly(disulfide)s. Business: trial wins for Roche's enicepatide, Vertex's inaxaplin, Roche/Ionis's sefaxersen, and Amgen's dazodalibep, capped by the EU's first CETP-inhibitor approval, obicetrapib.
2026-09-27 ⚗️ 7 💻 1 🏢 6
Today: 8 science papers spanning oral STAT6 and nano-PROTAC degraders, PLK4/BChE/STAT3 SAR, and conjugate chemistry, plus 6 business stories led by Lilly's China deal, Novo's Nanexa license, Xofluza pandemic licensing, and two AI-biotech funding rounds.
2026-09-24 ⚗️ 7 💻 2 🏢 4
Today: nine chemistry items — PTP1B/TCPTP degrader, CDK2 inhibitor INCB127443, TRPM7 leads, opioid-NPFF peptides, TrmD review, SMILES tool, Bayesian flow design, BACE-1 fragment growing, allosteric SHP2 — plus four business stories: Flagship's Pentagon deal, Celldex's Phase 3 data, Novo's Medicare terms, GSK's China ADCs.
2026-09-23 ⚗️ 8 💻 2 🏢 5
Today's digest: 10 science papers spanning virtual screening, covalent inhibitors, degraders, and SAR optimization against DYRK1A, CK1delta, PCNA, and HBV capsid targets, plus 5 business stories led by Telix's radiopharma merger, Iambic's AI-biotech IPO, and Winrevair's PAH label expansion.
2026-09-22 ⚗️ 5 💻 3 🏢 5
Today: 8 science items — CK1δ and PARP-1/CK2α degraders, PCNA and HBV capsid optimization, a DEL/ML benchmark — plus 5 business stories: Telix's ITM buyout, Alkermes' ADHD data, Novo's strategy day, a HUTCHMED-GSK deal, and BioNTech's vaccine halt.
2026-09-21 ⚗️ 6 💻 1 🏢 4
Today: 7 science papers — covalent fragments, PROTAC/CMA degraders, de novo peptide design, mutant-selective kinase inhibitors — plus 4 business stories: Novo's rebrand, a Novartis ALS setback, Roche's Boston hub, and BMS's Orum exit.
2026-09-19 ⚗️ 5 💻 2 🏢 7
A steady science day covering degraders, kinase structure, HDAC selectivity, hit-finding, AI screening QC, and ion-channel natural products, alongside a busy business day: one approval, one merger, a pricing deal, a startup launch, a financing round, and two trial setbacks.
2026-09-18 ⚗️ 7 💻 3 🏢 7
Science (10): Keap1-Nrf2, flavonoid AIs, TAAR1, TRIM24, HDAC4/7, STELLAR, CYP8B1, cMYC RIBOTAC, p38δ, thrombin DCC — hit-finding and SAR heavy. Business (7): Novo-Ascendis split, Sling raise, BioNTech win, SELLAS fail, Sionna cuts, Merck-PostEra M&A, AZ Enhertu reimbursement.
2026-09-17 ⚗️ 7 💻 1 🏢 4
Today: eight papers on E3 ligase structures, BBB-penetrant PROTACs, a WBP4 glue, ADC linkers, AI screening, oligonucleotide SAR, a DUBTAC platform, and an hCES2A probe — plus Vera's Phase 3 win, GSK's $750M deal, Encoded's $275M raise, and Merck layoffs.
2026-09-16 ⚗️ 6 🧬 1 💻 1 🏢 5
Today's digest covers 8 science and 5 business items: a strong showing for targeted protein degradation and AI-guided computational screening, plus new GPCR and covalent-chemoproteomics targets, alongside three major trial readouts including ivonescimab's rare survival win over Keytruda.
2026-09-15 ⚗️ 1 🏢 3
1 science pick: an HTS screen finds a known GABA-B modulator moonlighting as a cardiac MCU activator; 3 business stories: Biohaven's clinical hold days after a $795M SK Biopharmaceuticals deal, BioXcel's Chapter 11 with Teva as stalking-horse bidder, and Definium's second positive LSD Phase 3 readout in anxiety.
2026-09-14 ⚗️ 1 💻 1 🏢 1
A quiet day: 2 science picks — AI co-folding speeds AKR1B10 inhibitor discovery, and a simplified homocamptothecin ADC payload; 1 business story — Solstice Oncology's $225M Series A launch with a licensed CTLA-4 antibody from Harbour BioMed.
2026-09-13 ⚗️ 6 🏢 3
6 science picks: DEL macrocycle chemistry, an HIV inhibitor redesign, an oral GLP-1 blueprint, a malaria drug target, a B3GAT3 liver-cancer hit, and a VAV1 molecular glue; 3 business stories: AstraZeneca's breast-cancer miss, Scholar Rock's SMA approval, and Shionogi's Australia antibiotic clearance.
2026-09-12 ⚗️ 3 💻 1 🏢 3
Lighter day: 4 science picks — a Kalirin-Rac1 covalent glue, brain-penetrant CD38 inhibitors, an antibacterial screening framework, and a first NatA probe; 3 business stories — AstraZeneca's ctDNA-guided approval, BioMarin's Voxzogo data, and Evommune's second EVO756 setback.
2026-09-11 ⚗️ 9 💻 2 🏢 9
A packed day: 11 science picks span molecular glue/PROTAC degraders, hit-finding rigor, and a novel conjugate-release chemistry; 9 business stories include Bayer and AstraZeneca trial wins, a double Novartis Phase III setback, and fresh financing and licensing deals.
2026-09-03 ⚗️ 1 🏢 5
Today's digest covers one science pick — a selective molecular glue degrader — plus five business stories: Ultragenyx's Angelman trial failure, TScan's restructuring, Roche-Simcere's antibody licensing deal, GSK's mRNA flu vaccine reaching Phase 3, and ARPA-H's RNA manufacturing funding push.
2026-09-02 🏢 4
A business-news-only day -- no science items cleared the source bar. Covered: Eli Lilly's up-to-$2.88B Merida Biosciences buy, Alumis' subgroup win in lupus, Novartis's MS trial success, and uniQure's Huntington's therapy filing.
2026-09-01 🏢 1
Today's digest covers one business item: Novartis and Bristol Myers Squibb both paused autoimmune CAR-T trials after safety events -- three IEC-HS deaths at Novartis, milder reversible reactions at BMS.